CompletedNot Applicable

A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy

China1,285 participantsStarted 2022-08-18

Plain-language summary

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 1000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients using rebinim ® during general anesthesia and fiberoptic sedation
✓. Patients need to sign informed consent

Exclusion criteria

✕. Patients who are participating in or planning to participate in any interventional clinical trial
✕. The investigator considers that there are any other reasons for the patient's ineligibility for the study

What they're measuring

Adverse events

Timeframe: Within 3 days of receiving General anesthesia and bronchoscopy sedation

Trial details

NCT IDNCT05549791

SponsorJiangsu HengRui Medicine Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-06-21

View on ClinicalTrials.gov More General Anesthesia and Bronchoscopy Sedation trials